Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 11 (100.0%)

Trials by Status

active_not_recruiting150%
recruiting150%

Recent Activity

2 active trials
Showing 2 of 2
recruitingphase_1

Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis

NCT05455034
active_not_recruiting

Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism

NCT06130683

Clinical Trials (2)

Showing 2 of 2 trials
NCT05455034Phase 1

Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis

Recruiting
NCT06130683

Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism

Active Not Recruiting

All 2 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
2